← Back to Screener
Compass Therapeutics, Inc. Common Stock (CMPX)
Price$2.04
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-72.75%
Price vs S&P 500 (4W)11.48%
VGM Score22.66
Market Capitalization$367.38M
All Metrics
Book Value / Share (Quarterly)$1.04
P/TBV (Annual)1.21x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.30
Price vs S&P 500 (YTD)-70.17%
EPS (TTM)$-0.31
10-Day Avg Trading Volume5.03M
EPS Excl Extra (TTM)$-0.31
EPS (Annual)$-0.42
ROI (Annual)-33.79%
Cash / Share (Quarterly)$1.08
ROA (Last FY)-30.28%
EBITD / Share (TTM)$-0.33
ROE (5Y Avg)-36.42%
Cash Flow / Share (Annual)$-0.28
P/B Ratio1.97x
P/B Ratio (Quarterly)5.11x
Net Income / Employee (Annual)$-1,704,800
Net Interest Coverage (TTM)-240.71x
ROA (TTM)-26.35%
EPS Incl Extra (Annual)$-0.42
Current Ratio (Annual)15.02x
Quick Ratio (Quarterly)18.94x
3-Month Avg Trading Volume5.92M
52-Week Price Return-13.56%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.26
P/S Ratio (Annual)432.21x
Asset Turnover (Annual)0.01x
52-Week High$6.88
EPS Excl Extra (Annual)$-0.42
CapEx CAGR (5Y)-25.65%
26-Week Price Return-64.83%
Quick Ratio (Annual)14.96x
13-Week Price Return-63.11%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)19.04x
Enterprise Value$312.21M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-5808.82%
Cash / Share (Annual)$1.17
3-Month Return Std Dev145.33%
Net Income / Employee (TTM)$-1,278,400
ROE (Last FY)-33.79%
Net Interest Coverage (Annual)-233.80x
EPS Basic Excl Extra (Annual)$-0.42
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.31
ROI (TTM)-29.94%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.44
Price vs S&P 500 (52W)-37.92%
Year-to-Date Return-62.01%
5-Day Price Return-8.11%
EPS Normalized (Annual)$-0.42
ROA (5Y Avg)-33.12%
Net Profit Margin (Annual)-5808.82%
Month-to-Date Return-14.29%
Cash Flow / Share (TTM)$-0.32
EBITD / Share (Annual)$-0.45
Operating Margin (Annual)-6661.76%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-36.42%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.31
P/TBV (Quarterly)1.37x
P/B Ratio (Annual)4.85x
Book Value / Share (Annual)$1.10
Price vs S&P 500 (13W)-71.36%
Beta0.82x
Revenue / Share (TTM)$0.00
ROE (TTM)-29.94%
52-Week Low$1.61
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.10est. -0.10
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.38
4.38
4.36
4.29
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CMPXCompass Therapeutics, Inc. Common Stock | — | — | D | $2.04 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing antibody-based immunotherapies to treat cancer. The company uses proprietary antibody discovery platforms and bispecific engineering capabilities to design targeted therapeutic combinations with favorable manufacturing profiles. Its pipeline includes multiple candidates such as CTX-009, CTX-471, CTX-8371, and a VEGF-A bispecific, leveraging its StitchMabs and common light chain technologies to advance treatment options.